Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin as adjuvant/neoadjuvant therapy in early breast cancer
2019-002508-42Phase 3Active
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Standard (neo)adjuvant therapy + atorvastatin with Standard (neo)adjuvant therapy + placebo (2 arms). Primary endpoint: Invasive disease-free survival (IDFS). Started Oct 2019; status: active.
02
Drugs
atorvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002508-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002508-42.